{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T05:36:09Z","timestamp":1794634569092,"version":"4.9.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000090","name":"United States Department of Defense | United States Army | Army Medical Command | Congressionally Directed Medical Research Programs","doi-asserted-by":"publisher","award":["W81XWH1810236"],"award-info":[{"award-number":["W81XWH1810236"]}],"id":[{"id":"10.13039\/100000090","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006064","name":"Sontag Foundation","doi-asserted-by":"publisher","award":["Distinguished Scientist Award"],"award-info":[{"award-number":["Distinguished Scientist Award"]}],"id":[{"id":"10.13039\/100006064","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["1K08CA230179"],"award-info":[{"award-number":["1K08CA230179"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["5U01CA247576"],"award-info":[{"award-number":["5U01CA247576"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Neurofibromatosis type 1 (NF1) is a tumor predisposition syndrome caused by alterations in <jats:italic>NF1<\/jats:italic> gene that lead to tumor growth throughout the nervous system, which can cause morbidity and mortality, and transform to malignancy. NF1 gene replacement therapy, though promising, is hindered by <jats:italic>NF1<\/jats:italic> gene\u2019s large size and delivery challenges. We introduced a membrane-targeted, truncated neurofibromin comprising the GAP-related domain (GRD) fused to the KRAS4B C-terminal domain, which effectively inhibits the RAS signaling pathway and restores Schwann cell differentiation in an NF1 iPSC-derived model. For systemic application, we engineered an adeno-associated virus (AAV) vector using in vivo capsid evolution through sequential DNA shuffling and peptide library screening in a NF1 xenograft mouse model. This tailored vector, AAV-NF, exhibits greatly reduced liver uptake, enhanced tumor targeting across various NF1-related MPNST, neurofibromas and glioma models, and therapeutic efficacy in xenografts of MPNST. This study not only advances a viable AAV vector for NF1 treatment but also outlines a replicable strategy for vector and payload development in other monogenic and tumor-associated disease manifestations.<\/jats:p>","DOI":"10.1038\/s41467-025-63619-4","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T15:25:10Z","timestamp":1759159510000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5281-9091","authenticated-orcid":false,"given":"Ren-Yuan","family":"Bai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyi","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nihao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9098-1680","authenticated-orcid":false,"given":"Xiaojun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manzhu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hotae","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huazhen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karis","family":"Weisgerber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihong","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7116-0605","authenticated-orcid":false,"given":"Christine A.","family":"Pratilas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1049-0993","authenticated-orcid":false,"given":"Jaishri O.","family":"Blakeley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9436-6382","authenticated-orcid":false,"given":"Melissa L.","family":"Fishel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meritxell","family":"Carri\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2895-9857","authenticated-orcid":false,"given":"Eduard","family":"Serra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verena","family":"Staedtke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"key":"63619_CR1","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nrc3911","volume":"15","author":"N Ratner","year":"2015","unstructured":"Ratner, N. & Miller, S. J. A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor. Nat. Rev. Cancer 15, 290\u2013301 (2015).","journal-title":"Nat. Rev. Cancer"},{"key":"63619_CR2","doi-asserted-by":"publisher","first-page":"e210945","DOI":"10.1001\/jamanetworkopen.2021.0945","volume":"4","author":"JP Landry","year":"2021","unstructured":"Landry, J. P. et al. Comparison of cancer prevalence in patients with neurofibromatosis type 1 at an academic cancer center vs in the general population from 1985 to 2020. JAMA Netw. Open 4, e210945 (2021).","journal-title":"JAMA Netw. Open"},{"key":"63619_CR3","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1912735","volume":"382","author":"AM Gross","year":"2020","unstructured":"Gross, A. M. et al. Selumetinib in children with inoperable plexiform neurofibromas. N. Engl. J. Med. 382, 1430\u20131442 (2020).","journal-title":"N. Engl. J. Med."},{"key":"63619_CR4","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1093\/neuonc\/noac146","volume":"24","author":"MJ Fisher","year":"2022","unstructured":"Fisher, M. J. et al. Management of neurofibromatosis type 1-associated plexiform neurofibromas. Neuro Oncol. 24, 1827\u20131844 (2022).","journal-title":"Neuro Oncol."},{"key":"63619_CR5","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1200\/JCO.24.01034","volume":"43","author":"CL Moertel","year":"2025","unstructured":"Moertel, C. L. et al. ReNeu: a pivotal, phase IIb trial of mirdametinib in adults and children with symptomatic neurofibromatosis type 1-associated plexiform neurofibroma. J. Clin. Oncol. 43, 716\u2013729 (2025).","journal-title":"J. Clin. Oncol."},{"key":"63619_CR6","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S1470-2045(19)30277-3","volume":"20","author":"J Fangusaro","year":"2019","unstructured":"Fangusaro, J. et al. Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial. Lancet Oncol. 20, 1011\u20131022 (2019).","journal-title":"Lancet Oncol."},{"key":"63619_CR7","doi-asserted-by":"crossref","unstructured":"Shih, F. H., Chang, H. H. & Wang, Y. C. Utilizing adeno-associated virus as a vector in treating genetic disorders or human cancers. IUBMB Life (2024).","DOI":"10.1002\/iub.2896"},{"key":"63619_CR8","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","volume":"9","author":"JH Wang","year":"2024","unstructured":"Wang, J. H., Gessler, D. J., Zhan, W., Gallagher, T. L. & Gao, G. Adeno-associated virus as a delivery vector for gene therapy of human diseases. Signal Transduct. Target Ther. 9, 78 (2024).","journal-title":"Signal Transduct. Target Ther."},{"key":"63619_CR9","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.ccell.2020.03.007","volume":"37","author":"A Marusyk","year":"2020","unstructured":"Marusyk, A., Janiszewska, M. & Polyak, K. Intratumor heterogeneity: the rosetta stone of therapy resistance. Cancer Cell 37, 471\u2013484 (2020).","journal-title":"Cancer Cell"},{"key":"63619_CR10","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1002\/humu.23552","volume":"39","author":"M Carrio","year":"2018","unstructured":"Carrio, M. et al. Analysis of intratumor heterogeneity in Neurofibromatosis type 1 plexiform neurofibromas and neurofibromas with atypical features: Correlating histological and genomic findings. Hum. Mutat. 39, 1112\u20131125 (2018).","journal-title":"Hum. Mutat."},{"key":"63619_CR11","doi-asserted-by":"publisher","first-page":"17004","DOI":"10.1038\/nrdp.2017.4","volume":"3","author":"DH Gutmann","year":"2017","unstructured":"Gutmann, D. H. et al. Neurofibromatosis type 1. Nat. Rev. Dis. Prim. 3, 17004 (2017).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"63619_CR12","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41434-019-0080-9","volume":"26","author":"RY Bai","year":"2019","unstructured":"Bai, R. Y. et al. Feasibility of using NF1-GRD and AAV for gene replacement therapy in NF1-associated tumors. Gene Ther. 26, 277\u2013286 (2019).","journal-title":"Gene Ther."},{"key":"63619_CR13","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.molmed.2025.01.004","volume":"31","author":"B Henshey","year":"2025","unstructured":"Henshey, B., Carneiro, A., Lei, K., Schaffer, D. & Boulis, N. M. Adeno-associated viral vector targeted evolution for neurofibromatosis gene delivery. Trends Mol. Med. 31, 388\u2013398 (2025).","journal-title":"Trends Mol. Med."},{"key":"63619_CR14","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.cell.2017.06.009","volume":"170","author":"DK Simanshu","year":"2017","unstructured":"Simanshu, D. K., Nissley, D. V. & McCormick, F. RAS proteins and their regulators in human disease. Cell 170, 17\u201333 (2017).","journal-title":"Cell"},{"key":"63619_CR15","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1038\/labinvest.2016.88","volume":"96","author":"H Li","year":"2016","unstructured":"Li, H., Chang, L. J., Neubauer, D. R., Muir, D. F. & Wallace, M. R. Immortalization of human normal and NF1 neurofibroma Schwann cells. Lab Invest 96, 1105\u20131115 (2016).","journal-title":"Lab Invest"},{"key":"63619_CR16","doi-asserted-by":"publisher","first-page":"7497","DOI":"10.1073\/pnas.1607298113","volume":"113","author":"T Dunzendorfer-Matt","year":"2016","unstructured":"Dunzendorfer-Matt, T., Mercado, E. L., Maly, K., McCormick, F. & Scheffzek, K. The neurofibromin recruitment factor Spred1 binds to the GAP-related domain without affecting Ras inactivation. Proc. Natl. Acad. Sci. USA 113, 7497\u20137502 (2016).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"63619_CR17","doi-asserted-by":"publisher","first-page":"3124","DOI":"10.1074\/jbc.M115.703710","volume":"291","author":"Y Hirata","year":"2016","unstructured":"Hirata, Y. et al. Interaction between a domain of the negative regulator of the Ras-ERK pathway, SPRED1 protein, and the GTPase-activating protein-related domain of neurofibromin is implicated in legius syndrome and neurofibromatosis type 1. J. Biol. Chem. 291, 3124\u20133134 (2016).","journal-title":"J. Biol. Chem."},{"key":"63619_CR18","doi-asserted-by":"crossref","unstructured":"Mo, J. et al. Humanized neurofibroma model from induced pluripotent stem cells delineates tumor pathogenesis and developmental origins. J. Clin. Investig. 131, (2021).","DOI":"10.1172\/JCI139807"},{"key":"63619_CR19","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.stemcr.2019.01.001","volume":"12","author":"M Carrio","year":"2019","unstructured":"Carrio, M. et al. Reprogramming Captures the Genetic and Tumorigenic Properties of Neurofibromatosis Type 1 Plexiform Neurofibromas. Stem Cell Rep. 12, 411\u2013426 (2019).","journal-title":"Stem Cell Rep."},{"key":"63619_CR20","doi-asserted-by":"publisher","first-page":"5887","DOI":"10.1128\/JVI.00254-08","volume":"82","author":"D Grimm","year":"2008","unstructured":"Grimm, D. et al. In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses. J. Virol. 82, 5887\u20135911 (2008).","journal-title":"J. Virol."},{"key":"63619_CR21","doi-asserted-by":"crossref","unstructured":"Pekrun, K. et al. Using a barcoded AAV capsid library to select for clinically relevant gene therapy vectors. JCI Insight 4, (2019).","DOI":"10.1172\/jci.insight.131610"},{"key":"63619_CR22","doi-asserted-by":"crossref","unstructured":"Turk, A. N., Byer, S. J., Zinn, K. R. & Carroll, S. L. Orthotopic xenografting of human luciferase-tagged malignant peripheral nerve sheath tumor cells for in vivo testing of candidate therapeutic agents. J. Vis. Exp. (2011).","DOI":"10.3791\/2558-v"},{"key":"63619_CR23","doi-asserted-by":"publisher","first-page":"91","DOI":"10.2144\/000114381","volume":"60","author":"W Huang","year":"2016","unstructured":"Huang, W., Johnston, W. A., Boden, M. & Gillam, E. M. ReX: A suite of computational tools for the design, visualization, and analysis of chimeric protein libraries. Biotechniques 60, 91\u201394 (2016).","journal-title":"Biotechniques"},{"key":"63619_CR24","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/nbt.3440","volume":"34","author":"BE Deverman","year":"2016","unstructured":"Deverman, B. E. et al. Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain. Nat. Biotechnol. 34, 204\u2013209 (2016).","journal-title":"Nat. Biotechnol."},{"key":"63619_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33745-4","volume":"13","author":"TJ Gonzalez","year":"2022","unstructured":"Gonzalez, T. J. et al. Cross-species evolution of a highly potent AAV variant for therapeutic gene transfer and genome editing. Nat. Commun. 13, 5947 (2022).","journal-title":"Nat. Commun."},{"key":"63619_CR26","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41592-020-0799-7","volume":"17","author":"S Ravindra Kumar","year":"2020","unstructured":"Ravindra Kumar, S. et al. Multiplexed Cre-dependent selection yields systemic AAVs for targeting distinct brain cell types. Nat. Methods 17, 541\u2013550 (2020).","journal-title":"Nat. Methods"},{"key":"63619_CR27","doi-asserted-by":"publisher","first-page":"5367","DOI":"10.1158\/0008-5472.CAN-20-1365","volume":"80","author":"J Wang","year":"2020","unstructured":"Wang, J. et al. Combined Inhibition of SHP2 and MEK is effective in models of NF1-deficient malignant peripheral nerve sheath tumors. Cancer Res 80, 5367\u20135379 (2020).","journal-title":"Cancer Res"},{"key":"63619_CR28","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1158\/0008-5472.CAN-20-1992","volume":"81","author":"J Wang","year":"2021","unstructured":"Wang, J., Pollard, K., Calizo, A. & Pratilas, C. A. Activation of receptor tyrosine kinases mediates acquired resistance to MEK inhibition in malignant peripheral nerve sheath tumors. Cancer Res 81, 747\u2013762 (2021).","journal-title":"Cancer Res"},{"key":"63619_CR29","doi-asserted-by":"publisher","first-page":"110385","DOI":"10.1016\/j.celrep.2022.110385","volume":"38","author":"H Mazuelas","year":"2022","unstructured":"Mazuelas, H. et al. Modeling iPSC-derived human neurofibroma-like tumors in mice uncovers the heterogeneity of Schwann cells within plexiform neurofibromas. Cell Rep. 38, 110385 (2022).","journal-title":"Cell Rep."},{"key":"63619_CR30","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1038\/mt.2011.3","volume":"19","author":"NM Kotchey","year":"2011","unstructured":"Kotchey, N. M. et al. A potential role of distinctively delayed blood clearance of recombinant adeno-associated virus serotype 9 in robust cardiac transduction. Mol. Ther. 19, 1079\u20131089 (2011).","journal-title":"Mol. Ther."},{"key":"63619_CR31","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s40262-020-00967-y","volume":"60","author":"O Campagne","year":"2021","unstructured":"Campagne, O., Yeo, K. K., Fangusaro, J. & Stewart, C. F. Clinical pharmacokinetics and pharmacodynamics of selumetinib. Clin. Pharmacokinet. 60, 283\u2013303 (2021).","journal-title":"Clin. Pharmacokinet."},{"key":"63619_CR32","doi-asserted-by":"crossref","unstructured":"Bergoug, M. et al. Neurofibromin structure, functions and regulation. Cells 9, (2020).","DOI":"10.3390\/cells9112365"},{"key":"63619_CR33","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41586-021-04024-x","volume":"599","author":"A Naschberger","year":"2021","unstructured":"Naschberger, A., Baradaran, R., Rupp, B. & Carroni, M. The structure of neurofibromin isoform 2 reveals different functional states. Nature 599, 315\u2013319 (2021).","journal-title":"Nature"},{"key":"63619_CR34","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1038\/s41594-021-00687-2","volume":"28","author":"CJ Lupton","year":"2021","unstructured":"Lupton, C. J. et al. The cryo-EM structure of the human neurofibromin dimer reveals the molecular basis for neurofibromatosis type 1. Nat. Struct. Mol. Biol. 28, 982\u2013988 (2021).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"63619_CR35","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1016\/j.molcel.2022.03.011","volume":"82","author":"M Chaker-Margot","year":"2022","unstructured":"Chaker-Margot, M. et al. Structural basis of activation of the tumor suppressor protein neurofibromin. Mol. Cell 82, 1288\u20131296.e1285 (2022).","journal-title":"Mol. Cell"},{"key":"63619_CR36","doi-asserted-by":"publisher","first-page":"e2208960120","DOI":"10.1073\/pnas.2208960120","volume":"120","author":"LC Young","year":"2023","unstructured":"Young, L. C. et al. Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization. Proc. Natl. Acad. Sci. USA 120, e2208960120 (2023).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"63619_CR37","first-page":"2420","volume":"13","author":"DC Huang","year":"1993","unstructured":"Huang, D. C., Marshall, C. J. & Hancock, J. F. Plasma membrane-targeted ras GTPase-activating protein is a potent suppressor of p21ras function. Mol. Cell Biol. 13, 2420\u20132431 (1993).","journal-title":"Mol. Cell Biol."},{"key":"63619_CR38","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1158\/0008-5472.CAN-19-3682","volume":"80","author":"IA Prior","year":"2020","unstructured":"Prior, I. A., Hood, F. E. & Hartley, J. L. The frequency of Ras mutations in cancer. Cancer Res. 80, 2969\u20132974 (2020).","journal-title":"Cancer Res."},{"key":"63619_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-02694-1","volume":"11","author":"A Kagiava","year":"2021","unstructured":"Kagiava, A. et al. Efficacy of AAV serotypes to target Schwann cells after intrathecal and intravenous delivery. Sci. Rep. 11, 23358 (2021).","journal-title":"Sci. Rep."},{"key":"63619_CR40","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.ymthe.2018.01.018","volume":"26","author":"J Hordeaux","year":"2018","unstructured":"Hordeaux, J. et al. The neurotropic properties of AAV-PHP.B are limited to C57BL\/6J mice. Mol. Ther. 26, 664\u2013668 (2018).","journal-title":"Mol. Ther."},{"key":"63619_CR41","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.ymthe.2019.02.013","volume":"27","author":"J Hordeaux","year":"2019","unstructured":"Hordeaux, J. et al. The GPI-linked protein LY6A drives AAV-PHP.B transport across the blood-brain barrier. Mol. Ther. 27, 912\u2013921 (2019).","journal-title":"Mol. Ther."},{"key":"63619_CR42","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/0092-8674(92)90407-4","volume":"69","author":"JE DeClue","year":"1992","unstructured":"DeClue, J. E. et al. Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis. Cell 69, 265\u2013273 (1992).","journal-title":"Cell"},{"key":"63619_CR43","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1158\/2159-8290.CD-18-0156","volume":"9","author":"KJ Radomska","year":"2019","unstructured":"Radomska, K. J. et al. Cellular origin, tumor progression, and pathogenic mechanisms of cutaneous neurofibromas revealed by mice with Nf1 knockout in boundary cap cells. Cancer Discov. 9, 130\u2013147 (2019).","journal-title":"Cancer Discov."},{"key":"63619_CR44","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.ymthe.2023.01.010","volume":"31","author":"M Schulz","year":"2023","unstructured":"Schulz, M. et al. Binding and neutralizing anti-AAV antibodies: detection and implications for rAAV-mediated gene therapy. Mol. Ther. 31, 616\u2013630 (2023).","journal-title":"Mol. Ther."},{"key":"63619_CR45","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1016\/j.ymthe.2023.10.015","volume":"31","author":"D Duan","year":"2023","unstructured":"Duan, D. Lethal immunotoxicity in high-dose systemic AAV therapy. Mol. Ther. 31, 3123\u20133126 (2023).","journal-title":"Mol. Ther."},{"key":"63619_CR46","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1038\/s41416-021-01270-8","volume":"124","author":"S Gampala","year":"2021","unstructured":"Gampala, S. et al. Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours. Br. J. Cancer 124, 1566\u20131580 (2021).","journal-title":"Br. J. Cancer"},{"key":"63619_CR47","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ccr.2009.05.009","volume":"16","author":"LT McGillicuddy","year":"2009","unstructured":"McGillicuddy, L. T. et al. Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis. Cancer Cell 16, 44\u201354 (2009).","journal-title":"Cancer Cell"},{"key":"63619_CR48","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41596-018-0097-3","volume":"14","author":"RC Challis","year":"2019","unstructured":"Challis, R. C. et al. Systemic AAV vectors for widespread and targeted gene delivery in rodents. Nat. Protoc. 14, 379\u2013414 (2019).","journal-title":"Nat. Protoc."},{"key":"63619_CR49","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1093\/neuonc\/nor077","volume":"13","author":"RY Bai","year":"2011","unstructured":"Bai, R. Y., Staedtke, V., Aprhys, C. M., Gallia, G. L. & Riggins, G. J. Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme. Neuro Oncol. 13, 974\u2013982 (2011).","journal-title":"Neuro Oncol."},{"key":"63619_CR50","first-page":"vdab184","volume":"4","author":"V Staedtke","year":"2022","unstructured":"Staedtke, V. et al. Neutrophil depletion enhanced the Clostridium novyi-NT therapy in mouse and rabbit tumor models. Neurooncol Adv. 4, vdab184 (2022).","journal-title":"Neurooncol Adv."},{"key":"63619_CR51","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.omtm.2022.02.011","volume":"25","author":"JR Mendell","year":"2022","unstructured":"Mendell, J. R. et al. Testing preexisting antibodies prior to AAV gene transfer therapy: rationale, lessons and future considerations. Mol. Ther. Methods Clin. Dev. 25, 74\u201383 (2022).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"63619_CR52","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1258\/acb.2009.009077","volume":"46","author":"T Ito","year":"2009","unstructured":"Ito, T. et al. A convenient enzyme-linked immunosorbent assay for rapid screening of anti-adeno-associated virus neutralizing antibodies. Ann. Clin. Biochem 46, 508\u2013510 (2009).","journal-title":"Ann. Clin. Biochem"},{"key":"63619_CR53","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1089\/hgtb.2015.037","volume":"26","author":"A Meliani","year":"2015","unstructured":"Meliani, A. et al. Determination of anti-adeno-associated virus vector neutralizing antibody titer with an in vitro reporter system. Hum. Gene Ther. Methods 26, 45\u201353 (2015).","journal-title":"Hum. Gene Ther. Methods"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-63619-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-63619-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-63619-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T16:03:49Z","timestamp":1759161829000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-63619-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["63619"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-63619-4","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,29]]},"assertion":[{"value":"15 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A patent application on the new AAV vectors for NF1 gene replacement therapy with R.B. and V.S. as co-inventors has been provisionally filed by JHU (63\/697,752). The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8594"}}